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Abstract
Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disorder of the
central nervous system. Although pediatric and adult-onset MS have similar neurolog‐
ic symptoms, there are some differences from adults in radiologic findings, cognitive
features, clinical course, and diagnostic criteria of pediatric MS. Diagnostic criteria and
radiologic features of pediatric MS have been defined in recent years. There are no large,
randomized,  controlled  therapeutic  trials  in  pediatric  MS.  In  this  chapter,  clinical
characteristics,  diagnostic  criteria,  laboratory  findings,  differential  diagnosis,  and
treatment of pediatric MS are summarized.
Keywords: multiple sclerosis, pediatric multiple sclerosis, childhood multiple sclero‐
sis, demyelinating disorders, demyelination
1. Introduction
Multiple sclerosis (MS) is an autoimmune chronic inflammatory disease of the central nerv‐
ous system; it is characterized by demyelination and axonal loss. MS primarily affects young
adults. Recently, it has been increasingly recognized in children and adolescents. Approxi‐
mately 2–5% of all MS patients have onset before age 18 [1, 2]. Onset before 10 years of age occurs
in less than 1% of all patients. There are some differences, including clinical presentation,
magnetic  resonance  imaging  (MRI)  findings,  and  neuroimmunologic  features,  between
pediatric and adult MS patients. The first attack can be acute disseminated encephalomyelitis,
particularly in young children. Relapses are more frequent in pediatric MS patients than in
adults, though improvement is better. Cognitive impairment including linguistic dysfunction
and reduction in IQ scores also differs from adults. T2 lesion burden is higher in pediatric patients
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in MRI as compared to adult MS patients. These differences are more marked in prepuberal
children [3]. The still developing central nervous and immune systems may be responsible for
these differences. However, studies on pathogenesis and pathology of pediatric MS are limited.
2. Epidemiology
The incidence of pediatric MS is unknown, but its estimated prevalence has been reported to
be 1.35–2.5 per 100,000 children [4]. The gender ratio varies with the age of onset: in patients
older than 10 years, the female-to-male ratio is similar to adults; there is female dominance. In
children younger than 10 years old, the female-to-male ratio decreases. This difference may be
due to hormonal influence or gender-specific genetic influence on immunological reactivity
[5].
3. Etiology and risk factors
Pediatric MS has a complex etiology related to both genetic and environmental factors. Vitamin
D deficiency has been implicated as a risk factor for MS in children, as it is in adults. Mowry
et al. have demonstrated an association between relapse rate and vitamin D level in pediatric
MS patients [6]. Smoking has been considered as a risk factor in adults, whereas passive smoke
exposure has been recognized as a risk factor in children [7]. One of the most studied envi‐
ronmental risk factors is viral exposure and studies have found that viral exposure in child‐
hood may predispose some individuals to the development of MS. Epstein-Barr seropositivity
and serum anti-EBV antibody titers tend to be higher in MS patients than they are in normal
individuals. The relationship between the Epstein-Barr virus and MS has also been shown in
pediatric MS [8]. Another risk factor is obesity. Childhood and adolescent obesity has been
suggested as a risk factor for the development of MS in both adults and children [9]. Genetic
susceptibility is also a risk factor for MS. HLA-DRB1 locus has been associated with multiple
sclerosis in children. Twin studies have demonstrated a concordance rate of 27% in monozy‐
gotic twins. The incidence for first-degree relatives of patients with MS is 2–5%, whereas the
incidence for the general population is under 0.1% [10].
4. Pathogenesis
Multiple sclerosis is a neuroimmunologic disorder characterized pathologically by inflamma‐
tion, demyelination, and axonal loss. Neuropathological findings and animal models such as
experimental allergic encephalomyelitis support the immunopathogenesis in multiple
sclerosis. HLA Class II genes which are associated with MS risk are also related to the immune
system.
The first step in the immunopathogenesis of MS is peripheral activation of CD4+ T
lymphocytes in response to an antigen. This antigen is unknown. It has been suggested that
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molecular mimicry between this antigen and central nervous system antigens causes cross
reactivity. Subsequently, activated T lymphocytes migrate through the blood-brain barrier
into the central nervous system [10, 11]. Lymphocyte migration represents an important step
in MS pathogenesis. This multistep process includes adhesion, chemoattraction, and active
infiltration into the central nervous system. Adhesion molecules, chemokines, and cyto‐
kines play an important role in these steps [10]. α4β1 integrin (VLA-4, very late activating
antigen) is an adhesion molecule which is expressed on the lymphocyte surface and binds
to the vascular cell adhesion molecule-1 (VICAM-1) located on the endothelium. As a result
of this interaction, lymphocytes adhere to the endothelium and transmigrate across the
endothelial cell layer into the central nervous system [12]. Chemokines regulate migration
of immune cells into the brain; they also manipulate the lymphocyte transendothelial
migration and locomotion within the tissue along chemoattractant gradients. Reactivation
of infiltrating immune cells within the central nervous system leads to perivascular
inflammation and injury. This injury results in the release of additional central nervous
system antigens such as myelin proteins and leads to immune responses to these self-
antigens (antigen spreading/epitope spreading). T cells reactive to myelin proteins includ‐
ing myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), and myelin
proteolipid protein (PLP) are involved in the central nervous system inflammatory re‐
sponse of MS patients [10]. Myelin-reactive T cells have differences in MS patients as
compared with healthy controls. In MS patients myelin-reactive T cells differ by having
memory phenotype. Memory T cells play an important role in MS pathogenesis. Other
immune cells including proinflammatory and anti-inflammatory/regulatory CD4+ T cells
(helper T lymphocytes), CD8+ T cells (cytotoxic T lymphocytes), myeloid cell subsets, B cells,
and natural killer cells contribute to the pathogenesis of MS in adults. After activation by
antigen-presenting cells such as dendritic cells, naïve T cells differentiate into one of the
several subsets with different effector functions. Th1 lymphocytes secrete proinflammato‐
ry cytokines such as interferon gamma, while Th2 lymphocytes produce anti-inflammato‐
ry cytokines such as interleukin 4, interleukin 10. The imbalance between proinflammatory
and anti-inflammatory cytokines has been invoked in MS pathogenesis. Proinflammatory
cytokines play crucial roles in MS pathogenesis including peripheral immune activation,
enhancement of trafficking of activated immune cells into the CNS, and direct damage to
oligodendrocytes, myelin, and axons [10, 12]. Th17 lymphocytes are also a subgroup of CD4+
T cells that produce the proinflammatory cytokines interleukin 17A and interleukin 17F.
Th17 lymphocytes are developmentally distinct from Th1 and Th2 lineages. Interleukin 23
produced by macrophages and dendritic cells contributes to development of Th17. High
Th17 to Th1 ratios are associated with T cell infiltration and inflammation in the brain
parenchyma [13]. The presence of interleukin 17 in MS lesions and increased interleukin 17
expression in both blood and CSF of MS patients have been demonstrated [14, 15]. Other
subgroups of T cells also have been implicated in the immunopathogenesis of MS. Regula‐
tory T (Treg) cells control potentially pathogenic autoreactive T cells. Studies demonstrat‐
ed that regulatory T cell functions are altered in MS. In a study, similar T cell responses to
myelin basic protein and myelin oligodendrocyte glycoprotein epitopes have been found in
both adult and pediatric MS patients [16]. Vargas Lowy demonstrated increased CD4+ T
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cell proliferation to myelin peptides in children with MS and also found an increased
proportion of dividing CD4+ T cell to myelin peptides with a memory phenotype which
produced interleukin 17 [10].
Humoral immunity has also been implicated in MS pathogenesis. B lymphocytes, plasma cells,
immunoglobulins, and complement deposition have been shown in MS lesions. Anti-myelin
oligodendrocyte glycoprotein antibodies (anti-MOG) have been reported in pediatric cases
with inflammatory demyelinating diseases, predominantly in children with ADEM-like first
episodes and in pediatric MS patients younger than 10 years of age at disease onset. Anti-MOG
antibodies have also been observed in pediatric patients with recurrent optic neuritis and
seronegative NMO [10, 17]. The presence of anti-MOG antibodies has been reported in a
subgroup of adults with seronegative NMO but only rarely in adults with MS [18]. Moreover,
antibody-independent functions of B lymphocytes such as cytokine production play a role in
MS immunopathogenesis.
Neurodegeneration  and  axonal  damage  are  other  processes  in  the  pathogenesis  of  MS.
Mechanisms of axonal damage in multiple sclerosis include a specific immunologic attack on
axons;  the  presence  of  soluble  mediators  such as  proteases,  cytokines,  and free  radicals
released during the inflammatory process and lack of neurotrophic factors provided to the
axon by oligodendrocytes as a result of chronic demyelination [10, 19].
5. Pathology
The cellular content of MS lesions includes primarily T lymphocytes (CD4+ and CD8+) and
macrophages. Lucchinetti et al. have described four distinct pathological patterns of demye‐
lination in autopsy and biopsy samples from adult MS patients. Patterns I and II showed T
cell/macrophage inflammation and there was also T cell plus antibody-mediated autoim‐
mune damage in pattern II. Patterns III and IV were suggestive of a primary oligodendro‐
cyte  dystrophy.  Oligodendrocyte  apoptosis  or  death  and  lesser  macrophage-T  cell
inflammation  were  observed  in  patterns  III  and IV  [20].  In  another  study,  Trapp et  al.
demonstrated axonal damage in normal appearing white matter [21]. Additionally, subpial
cortical, intracortical, and leukocortical lesions were found in adult-onset multiple sclerosis
patients' biopsy specimens. Immune cells were also identified within the pia-arachnoid in
adult-onset multiple sclerosis and ectopic B-cell follicles with germinal centers were detect‐
ed  in  the  meninges  of  patients  with  secondary  progressive  multiple  sclerosis.  All  these
pathological findings were identified in adult patients [10, 22, 23]. Neuropathological studies
are limited in pediatric multiple sclerosis [10]. Tumefactive demyelinating lesions have been
investigated in pediatric patients with MS [24]. The pathological characteristics of tumefac‐
tive demyelinating lesions include relative axonal preservation, perivascular and parenchy‐
mal lymphocyte and macrophage inflammation [25].
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6. Diagnostic criteria
In 2007, the International Pediatric Multiple Sclerosis Study Group (IPMSSG) proposed a
consensus on definitions for pediatric acquired demyelinating disorders of the central nervous
system and pediatric MS. Pediatric MS referred to “children” (under the age of 10) and
“adolescents” (aged 10 and above but younger than 18) in this definition. In 2012, the study
group revised the criteria in consideration of studies that had applied 2007 pediatric MS criteria
and the 2010 revised McDonald’s criteria for adults [26–28].
According to the 2012 revised criteria, pediatric MS can be satisfied by any of the following:
• Two or more non-encephalopathic (e.g. not ADEM-like) clinical central nervous system
(CNS) events with a presumed inflammatory cause, separated by more than 30 days and
involving more than one area of the CNS.
• One non-encephalopathic episode typical of MS which is associated with MRI findings
consistent with the 2010 revised McDonald criteria for DIS (dissemination in space) and in
which a follow-up MRI shows at least one new enhancing or non-enhancing lesion consis‐
tent with DIT (dissemination in time) MS criteria.
• One ADEM attack followed by a non-encephalopathic clinical event, three or more months
after the onset of symptoms, which is associated with new MRI lesions that fulfill the 2010
revised McDonald DIS criteria.
• A first single, acute event that does not meet ADEM criteria and whose MRI findings are
consistent with the 2010 revised McDonald criteria for DIS and DIT (applies only to children
≥ 12 years old).
7. Clinical features
Most of the patients with pediatric MS have a relapsing remitting course. A primary pro‐
gressive course is extremely rare in pediatric MS. The definition of an attack (relapse/exacer‐
bation) in pediatric MS is similar to that in adults. An attack is defined as "the appearance of
new symptoms and neurologic signs, or worsening of old symptoms and signs due to an
acute inflammatory demyelinating event in the CNS, with duration of at least 24 hours in
the absence of fever or infection," and the onset of the attack should be separated from the
onset of a previous attack by at least 30 days [27].
Visual, sensory, motor, brainstem, cerebellar symptoms, sphincter, and cognitive dysfunctions
may also occur in pediatric MS, as they do in adults. Polysymptomatic and ADEM-like onset
are more common in prepuberal patients, particularly in very young children. Visual and
sensory symptoms may go unnoticed in very young children. In adolescents, the presentation
of monosymptomatic and sensorimotor symptoms is frequent, and optic neuritis is the most
common initial presentation. The interval between the initial demyelinating event and the
second attack varies, and this interval may be longer in very young children. Relapses are more
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frequent and may be more severe in pediatric patients but recovery is often better than it is in
adults. The accumulation of disability takes a long time in pediatric MS; however, over the
long term, patients can become disabled at a younger age. The transition to secondary
progressive MS occurs at a younger age in pediatric-onset MS than in adult-onset MS. The risk
of transition to secondary progressive MS in pediatric patients is associated with a higher
frequency of relapses and shorter intervals between attacks in the first few years of the disease
[2, 29–31].
Cognitive disturbance is an important feature in pediatric MS. Cognitive impairment can occur
even in the first few years of the disease and does not correlate with physical disability, number
of relapses, and disease duration. The onset of multiple sclerosis in very young children
increases the risk of cognitive impairment [3]. In adult MS patients, the most commonly
affected cognitive functions include processing speed, visual-spatial function, memory, and
executive functions. The most commonly affected cognitive areas in pediatric MS are attention
span, processing speed, and visual-motor skills as adults. Receptive language, verbal fluency,
and intelligence also are affected in pediatric MS, and they are affected differently than they
are in adult MS. Linguistic involvement (verbal fluency, naming, and comprehension) is an
important neuropsychological difference between pediatric and adult-onset MS [32, 33].
Pediatric MS patients are also at risk for a lower IQ [3]. Differences in cognitive dysfunctions
between pediatric MS and adult MS may be due to the effect of inflammatory demyelination
on the developing central nervous system and neuronal networks. All patients with pediatric
MS should be checked for cognitive dysfunction because it occurs in the early stages of the
disease and is unrelated to physical disability [29, 30, 33].
Psychiatric disorders such as depression or anxiety are common in pediatric MS, as they are
in adults. Fatigue is also reported in patients with pediatric MS. Cognitive impairment,
depression, and fatigue disrupt the child’s academic performance and quality of life [3].
8. Diagnostic evaluation
8.1. Magnetic resonance imaging features
MRI is the most important paraclinical tool for the diagnosis of MS, and it also provides
information for differential diagnosis.
Demyelinating plaques are demonstrated as an increased signal on T2 and FLAIR sequences
and are typically located in deep white matter, corpus callosum, periventricular zone,
juxtacortical, and posterior fossa. Hypointense lesions occur on T1 sequences. These hypoin‐
tense lesions are named “black holes.” Black holes are a result of tissue loss due to previous
inflammatory events. Acute MS plaques may appear to be T1 hypointense as a result of
transient edema, but these are not true T1-black holes. T1 hypointensity may remain for months
after an acute event with such lesions evolving to isointensity (loss of edema or repair) or
persisting as chronic, permanent hypointensity [34]. Active demyelinating plaques may show
gadolinium enhancement due to a blood-brain barrier breakdown and enhancement is often
incomplete around the periphery (open ring sign) (Figures 1 and 2).
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Figure 1. Large, hyperintense lesions on T2-weighted sequences.
Figure 2. Gadolonium enhanced demyelinating plaques and black holes on T1-weighted sequences.
MRI findings in McDonald’s diagnostic criteria are important and provide a diagnosis of MS
at the first demyelinating event. According to McDonald’s diagnostic criteria, dissemination
in space (DIS) can be demonstrated by one or more T2 lesions in at least two of four areas of
the CNS (periventricular, juxtacortical, infratentorial, spinal cord) and dissemination in time
(DIT) can be demonstrated by a new T2 and/or gadolinium-enhancing lesion(s) on a follow-
up MRI, with reference to a baseline scan, irrespective of the timing of the baseline MRI or the
simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing lesions at
any time [10]. These criteria have been found to be highly sensitive (100%) and highly specific
(86%) for children older than 12 years with non-ADEM presentation, but they may not be
appropriate for young children [35].
There are some differences in MRI findings between children and adults, particularly in
prepuberal cases: T2-hyperintense lesion volume and lesion load in the infratentorial area are
higher in children than they are in adults; first presentation may be as ADEM; there is an
increased incidence of larger, tumefactive lesions in young children; spinal cord lesions may
be longer than three vertebral segments in children with MS as in neuromyelitis optica [29, 36].
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8.2. Cerebrospinal fluid (CSF) features
Analysis of CSF provides information about both the inflammatory process and differential
diagnosis such as infection and malignancy. Cell count, presence of oligoclonal bands, and IgG
index are examined in CSF analysis. A mild lymphocytic pleocystosis may be seen in children,
but it has been shown that children younger than 11 years have more neutrophils in the CSF
than older children. Oligoclonal band positivity has been found in 92% of patients with
pediatric MS [37, 38]. An increased IgG index is more common in adolescents than in young
children.
8.3. Evoked potentials
Evoked potentials help to demonstrate subclinical demyelination and to evaluate prior
demyelination [39]. Visual evoked potentials are more informative than brainstem auditory
and somatosensory evoked potentials.
9. Differential diagnosis
Other immune-mediated central nervous system demyelinating disorders (clinically isolated
syndrome, acute disseminated encephalomyelitis, neuromyelitis optica) must be excluded in
pediatric patients presenting a first demyelinating attack.
Clinically isolated syndrome (CIS) is a monofocal (optic neuritis, brainstem syndrome,
transverse myelitis, cerebellar syndrome, or hemispheric syndrome) or polyfocal clinical CNS
event with a presumed inflammatory demyelinating cause without a prior clinical history of
a CNS demyelinating disease and encephalopathy. MRI features do not meet McDonald’s
criteria. Therefore, a follow-up check for the possibility of developing MS is necessary;
however, the likelihood of developing MS is low in patients with a normal brain MRI [28].
Acute disseminated encephalomyelitis (ADEM) is an inflammatory demyelinating disease
which is characterized by acute encephalopathy and polyfocal neurologic deficits. Encephal‐
opathy is an important feature and diagnostic criterion. Encephalopathy is defined as an
alteration in consciousness or behavioral change unexplained by fever, systemic illness, or
postictal symptoms in IPMSSG criteria 2012. Encephalopathy is an unexpected finding in MS.
MRI features are also defined for pediatric ADEM in the 2012 IPMSSG criteria [28]. Diffuse,
large (>1–2 cm), poorly demarcated hyperintense lesions are detected in cerebral white matter
on T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences; T1 hypointense
lesions are rare and deep gray matter lesions can be present in the thalamus or basal ganglia.
White matter lesions are multiple, bilateral, and asymmetrical in the cerebral hemispheres,
cerebellum, brainstem, and spinal cord. Deep gray matter lesions are usually symmetrical and
more characteristic of ADEM than of MS. The presence of T1 hypointense lesions in white
matter leads to a diagnosis of MS. Periventricular lesions are less common. Cerebrospinal fluid
(CSF) oligoclonal bands are rarely observed and usually transient in ADEM. Anti-MOG
antibodies may be transiently present in the serum. ADEM is usually a monophasic disorder.
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Clinical and radiologic findings may fluctuate in the first 3 months after the onset of disease.
A second attack of ADEM may occur rarely, and it is named “multiphasic ADEM” [28]. This
second ADEM event can involve either new neurologic symptoms and MRI findings or the re-
emergence of prior neurologic symptoms and MRI findings. In the 2012 IPMSSG criteria,
multiphasic ADEM is defined as two episodes consistent with ADEM separated by 3 months
but not followed by any further events [28]. Sometimes pediatric ADEM may be the first
manifestation of pediatric MS. Mikaeloff et al. showed that 18% of patients with pediatric
ADEM had a second attack suggesting MS [40]. The second attack usually occurs within 2
years of the initial event.
Neuromyelitis optica (NMO) is an inflammatory disorder characterized by severe acute
transverse myelitis and optic neuritis. Pediatric NMO can be monophasic or relapsing. Optic
neuritis and myelitis are more severe in NMO and the prognosis is worse than it is for MS.
Atypical presentations such as encephalopathy, persistent hiccups, nausea, and vomiting may
occur. A brain MRI does not meet the criteria for MS and can show lesions in the supratentorial
area, periaquaductal gray matter, hypothalamus, medial thalamus, dorsal pons, and medulla.
The presence of longitudinally extensive spinal cord lesions (more than three vertebral
segments) in a spinal MRI is an important finding and a supportive criterion. Anti-aquaporin-4
IgG seropositivity is another supportive criterion and it is 99% specific and 60–70% sensitive
in children [41]. CSF oligoclonal bands are generally absent.
Other causes such as vasculitis, vascular, infectious, or neoplastic diseases must be excluded
in pediatric patients with acute neurologic deficits. The presence of encephalopathy, persistent
headaches, fever, polyneuropathy, and hearing loss, the involvement of other organs such as
arthritis, skin rashes, oral/genital ulcers, lymphadenopathy, nephropathy, or hepatopathy
with a progressive course should be suggestive of other causes. A progressive course and the
involvement of the peripheral nervous system usually occur in mitochondrial diseases or
neurometabolic disorders such as leukodystrophies. The diseases that should be kept in mind
in the differential diagnosis are shown in Table 1. Markedly elevated pleocytosis, low glucose,
and increased protein in CSF analysis should rouse suspicions. Persistent gadolinium en‐
hancement and continued enlargement of lesions, leptomeningeal enhancement, T2 hyperin‐
tensities in the basal ganglia, thalamus, and hypothalamus, and calcifications in an MRI should
also eliminate the diagnosis of MS.
Other demyelinating disorders
   Clinically isolated syndrome
   ADEM
   Neuromyelitis optica
Vasculitis/inflammatory diseases
   Primary CNS angiitis
   Systemic lupus erythematosus
   Sjögren syndrome
   Behcet disease
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   Neurosarcoidosis
Cerebrovascular disorders
İnfection
   Neurborreliosis
   Tuberculosis
   Viral encephalitis
   HIV
   Progressive multifocal leukoencephalopathy (PML)
Neurometabolic/genetic disorders
   Mitochondrial diseases
   Leukodystrophies
Neoplasm
   CNS lymphoma
   Other CNS tumors
Table 1. Differential diagnosis of pediatric MS.
10. Treatment
10.1. Treatment of the acute demyelinating attack
A mildly acute demyelinating attack that does not impair the patient's functions may not
require treatment. The first option in the treatment of an acute demyelinating attack is a high-
dose intravenous corticosteroid. Corticosteroids increase the speed of recovery and reduce the
number of gadolinium-enhancing lesions on an MRI. The presumed mechanisms of action are
modification of cytokine responses, reduction in T cell activation, and reduction in blood-brain
barrier permeability. Intravenous corticosteroid is administered as 20–30 mg/kg (up to 1 g/
day) methyl prednisolone over 3–5 days in children. There is no consensus on tapering oral
corticosteroid. Oral prednisone may be administered to patients with incomplete recovery
after intravenous treatment. Plasma exchange can be considered for patients with severe, life-
threatening attacks or patients who were unresponsive to intravenous steroid treatment. The
typical course is 5–7 exchanges over the course of 10–14 days. Plasma exchange therapy is an
invasive treatment; its side effects include infection, blood clotting issues, and electrolyte
disturbances. Another option is intravenous immunoglobulin (IVIG) if the steroids are
contraindicated or the response is inadequate. There have been no controlled studies for the
efficiency of this treatment in pediatric MS. IVIG influences cytokine production, T cell
proliferation, and autoantibodies against myelin. It is given at a dose of 2 g/kg over 2–5 days.
Side effects include fever, headache, aseptic meningitis, thromboembolism, and allergic
reactions. Severe allergic reactions may develop in people with IgA deficiency; therefore,
serum IgA levels should be examined before treatment [42, 43].
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10.2. Disease-modifying therapy
The aims of treatment are to reduce disease activity, prevent disability, and preserve cognitive
functions. Therefore, it is recommended to start treatment at an early stage.
First-line disease-modifying therapy includes interferon beta and glatiramer acetate. These
drugs are used in adults for 15–20 years. Their efficacy, side effects, and safety are well known
in adults. Both interferon beta and glatiramer acetate reduce relapse rates by approximately
30% and the accrual of new lesions on the MRI. There have been no randomized controlled
trials in pediatric patients.
Glatiramer acetate is a synthetic amino acid polymer that resembles myelin basic protein. Its
mechanism is not clear. It modulates T cells, shifts the population of T cells from proinflam‐
matory Th1 cells to regulatory Th2 cells, and reduces antigen presentation. Standard dosage
is 20 mg daily by subcutaneous injection. Its side effects include injection reactions, lipoatrophy
at injection sites, chest pain, and a post-injection reaction (anxiety, flushing, palpitations,
dyspnea, and chest pain) [42–44].
Interferon beta inhibits autoreactive T cells, increases production of anti-inflammatory
cytokines, reduces proinflammatory cytokines, and decreases the migration of inflammatory
cells into CNS. There are two subgroups: interferon beta 1a and 1b. Interferon beta 1a is given
three times a week at a dose 22 or 44 µg via subcutaneous injection or intramuscularly at a
dose of 30 µg a week. A pegylated form of interferon beta 1a is used in adults, but the safety
and efficacy of this form in children and adolescents have not been established. The standard
dose of interferon beta-1b is 0.25 mg (8 MIU), injected subcutaneously every other day. Dose
titration is recommended at the start of treatment for interferons. Most pediatric patients
tolerate the adult dose. The most frequent side effects are flu-like symptoms, injection site
reaction, transient transaminase elevation, bone marrow suppression, thyroid dysfunction,
and depression. Paracetamol and ibuprofen are effective in managing the flu-like symptoms.
Liver transaminases, blood counts, and a thyroid function test should be carried out following
the treatment.
The aim of disease-modifying therapy is to reduce clinical and radiological disease activity.
Disease activity is defined as clinical relapses, new or enlarging lesions on an MRI, or gadoli‐
nium-enhancing lesions on an MRI. When the first-line disease-modifying therapy remains
insufficient to reduce disease activity, second-line therapies can be used. The second-line
therapies that have been used in pediatric MS include natalizumab, rituximab, and cyclo‐
phosphamide [42–44].
Natalizumab is a humanized monoclonal antibody. Natalizumab selectively binds to the 4-
integrin component of adhesion molecules found in lymphocytes, monocytes, eosinophils and
inhibits the α4-mediated adhesion of leukocytes to their counter-receptors. It decreases clinical
relapse rate by about 70% and reduces the accumulation of new or enlarging T2 hyperintense
lesions. Natalizumab is given at a dose of 300 mg intravenously every 4 weeks. Its side effects
include hypersensitivity and headaches. The most serious risk is progressive multifocal
leukoencephalopathy (PML) in adults. This fatal risk is higher in patients who have been
exposed to the JC virus and have been treated with immunosuppressive drugs previously.
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There is also a relationship between the duration of natalizumab therapy and an increased
risk. There have been no controlled, randomized trials in pediatric MS to date.
Rituximab is a monoclonal antibody. It selectively depletes CD20+ B lymphocytes. There have
been no controlled, randomized trials. Salzer et al. suggested that rituximab treatment is safe,
effective, and well tolerated in their case series with pediatric MS [45].
Trials on the safety and efficacy of new oral therapies including fingolimod, dimethyl fuma‐
rate, and teriflunamide in pediatric MS patients have not been finalized.
10.3. Symptomatic treatment
Spasticity, fatigue, tremor, neuropathic pain, paroxysmal symptoms, epileptic seizures,
bladder dysfunctions, and depression can be persistent symptoms in MS and affect patient’s
quality of life. Medical drugs can be effective in the treatment of these symptoms as in adult
patients.
Baclofen, tizanidine, and benzodiazepines are effective for spasticity. Amantadine, modafinil,
methylphenidate can be used for fatigue. Antiepileptic drugs such as carbamazepine, gaba‐
pentine are effective for both paroxysmal symptoms and neuropathic pain [42]. Anticholiner‐
gic agents (oxybutynin, tolterodine) can be used for detrusor hyperreflexia, and desmopressin
may be beneficial for nocturia.
10.4. Rehabilitation
The aim of MS rehabilitation is to reduce symptoms including spasticity, gait disturbances,
imbalance, bladder-bowel dysfunction, speech and swallowing disorders, fatigue, pain and
improve quality of life. Rehabilitation interventions for MS symptoms include methods such
as exercise (stretching/strengthening), gait training, endurance training, aerobic training,
hydrotherapy, physiotherapy, exercise-pelvic floor training, occupational therapy, psycho‐
logical training [46]. Rehabilitation interventions should be selected according to patient's
characteristics such as age and functional deficits.
Cognitive rehabilitation is an important part of MS rehabilitation, but there is no specific
cognitive rehabilitation intervention for pediatric MS. Rehabilitative strategies include
rehabilitation of attention and language based on other disease such as trauma, stroke, and
tumor [47].
11. Conclusion
Two to 5% of all MS patients have their first attack during childhood or adolescence. Pediatric
MS has different clinical features from adult-onset MS, particularly in very young children.
ADEM can occur as first attack in children, especially those under 10 years of age. The relapse
rate in pediatric MS is higher than in adult MS, but recovery from relapse is better than in
adults. However, the onset of secondary progression occurs at a younger age as compared
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with adult-onset MS. The primary progressive form of MS is extremely rare in pediatric
patients. Primary progressive course should suggest other diagnoses in children. Cognitive
impairment is one of the most important causes of disability and has different characteris‐
tics from adults. Linguistic dysfunction and decrease in IQ scores can occur during the first
year of disease. Despite all these differences from adult MS, the therapeutic approach is based
on information in adult MS. There are no randomized controlled trials on efficacy and safety
of  immunomodulatory and immunosuppressive drugs.  Studies on pathogenesis  are also
limited in pediatric MS. One of the most important differences in the pathogenesis of pediatric-
onset and adult-onset MS is the presence of anti-MOG antibodies in children. More studies
on pathogenesis will provide insight into clinical differences and the development of more
safe and effective treatment.
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